THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.
28 May 2024
Graft Polymer (UK) Plc
("Graft Polymer" or the "Company")
Filing of US Provisional Patent for Substance Use Disorders Treatment
Graft Polymer (UK) Plc (LSE: GPL) announces that it has filed a utility patent application (provisional) with the United States Patent and Trademark Office (USPTO) for the use of its proprietary and patented self-nanoemulsifying drug delivery systems (SNEDDS) platform for the delivery of drugs for the treatment of substance use disorders.
Patent Filing Overview
The provisional patent application, titled 'Composition and methods for substance use disorders (SUDS) using a self-nanoemulsifying drug delivery systems (SNEDDS)', covers the innovative application of Graft Polymer's SNEDDS platform to enhance the bioavailability, pharmacokinetics, and stability of therapeutics used in the treatment of substance use disorders many of which have poor solubility, leading to suboptimal drug delivery and posing an obstacle to successful formulation. This approach aims to leverage the Company's existing advanced biopolymer expertise to address significant unmet medical needs in addiction therapy.
Strategic Significance
The filing of this patent marks further progress in the Company's strategic focus on the healthcare industry, following the disposal of its industrial plastic manufacturing unit, Graft Polymer D.O.O, as announced on 3 May 2024. This disposal has enabled the Company to focus its attention and resources on its Graft Bio division, which represents, in the Directors' opinion, strong prospectivity through its intellectual property (IP), licensing agreements, and sales contracts.
Anthony Tennyson, CEO commented
"We are delighted to announce this progress in leveraging our existing biopolymer intellectual property for important healthcare applications with substantial unmet medical needs."
Enquiries
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director
Email: anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive Director
Email: yifat@graftpolymer.com
Allenby Capital (Broker)
Nick Naylor / Liz Kirchner (Corporate Finance)
Guy McDougall (Sales)
+44 (0) 20 3328 5656
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
